DFX Intelligence
Borrowers
196 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Pharmaceuticals” (remove)
Start from
196 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| Caerus US 1, Inc Life sciences | unattributed | 9 | at least $970M | 98c | 0 pts | May 25, 2029 | Sep 30, 2022 |
| Bamboo US BidCo LLC Life sciences | unattributed | 21 | at least $903M | 101c | 17 pts | Oct 1, 2029 | Dec 31, 2021 |
| Karo Kairos Intermediateco AB Life sciences | unattributed | 1 | at least $764M | 99c | n/a | Aug 26, 2032 | Sep 30, 2025 |
| P••• B••••• L•• Life sciences | unattributed | 9 | at least $381M | 101c | 1 pts | Mar 1, 2032 | Dec 31, 2022 |
| C•••••••• I•• Life sciences | C••••••• D••••••• • R•••• L•• inferred | 13 | at least $338M | 101c | 6 pts | Oct 1, 2029 | Sep 30, 2022 |
| D•• C••••••••• H••••••• P•• L•• • Life sciences | unattributed | 1 | at least $318M | 105c | n/a | Oct 29, 2032 | Sep 30, 2025 |
| A••••• B•••••• S•••••• I••••••••• L•• Life sciences | unattributed | 13 | at least $297M | 100c | 1 pts | Oct 1, 2030 | Dec 31, 2022 |
| O• H••••••••• G••••• I•• Life sciences | Sponsor not establishedpossible: K••••••• • C•••••• (a company of this name is on the sponsor's portfolio page) | 16 | at least $277M | 101c | 1 pts | Jan 1, 2031 | Dec 31, 2021 |
| A•••• A• F•••• P•• L•• Life sciences | unattributed | 3 | at least $258M | 97c | 0 pts | May 27, 2033 | Mar 31, 2026 |
| T••••••• H•••••••• I•• Life sciences | unattributed | 7 | at least $258M | 101c | 1 pts | May 12, 2032 | Dec 31, 2021 |
| F••••• P••••• H•••••••• I•• Life sciences | unattributed | 6 | at least $257M | 98c | 1 pts | Nov 6, 2031 | Dec 31, 2024 |
| C••••••• C•••• P•••••• I•• Life sciences | unattributed | 1 | at least $200M | 100c | n/a | Dec 18, 2031 | Dec 31, 2024 |
| N• K••••• B••••• I•• Life sciences | Sponsor not establishedpossible: C••••••• C•••••• M••••••••• L•• (a company of this name is on the sponsor's portfolio page) | 7 | at least $198M | 100c | 0 pts | Jan 1, 2033 | Dec 31, 2022 |
| S•••••• A• Life sciences | unattributed | 2 | at least $149M | 112c | n/a | Feb 27, 2030 | Mar 31, 2025 |
| B••••••• B••••••• B•••• S•• Life sciences | unattributed | 1 | at least $143M | 96c | n/a | Oct 7, 2032 | Mar 31, 2026 |
| R••• C•••••••• I••••••••• I••• I•• Life sciences | unattributed | 14 | at least $139M | 99c | 1 pts | Apr 12, 2032 | Dec 31, 2024 |
| P••••••••• H••••••• C••• Life sciences | unattributed | 3 | at least $138M | 99c | 3 pts | Jun 21, 2030 | Jun 30, 2024 |
| A•••• A•••• S• B•••• P••• L•• Life sciences | unattributed | 1 | at least $124M | 98c | n/a | Mar 19, 2033 | Jun 30, 2026 |
| P••••••• M•••• A• Life sciences | Sponsor not establishedpossible: C•• E••••• P••••••• I• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $110M | 102c | 0 pts | Sep 17, 2031 | Sep 30, 2023 |
| A•• V••••• Life sciences | Sponsor not establishedpossible: R•••• C•••••• G••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $100M | 100c | n/a | Mar 27, 2027 | Jun 30, 2024 |
| P•• F•••••••• M••••• S•• L•• Life sciences | unattributed | 2 | at least $98.0M | 100c | 0 pts | Feb 13, 2032 | Sep 30, 2024 |
| S••••••• R• A••••••••• L•• Life sciences | unattributed | 3 | at least $90.6M | 100c | 1 pts | Mar 1, 2033 | Mar 31, 2026 |
| 1•••••• B• L•• Life sciences | unattributed | 3 | at least $90.6M | 99c | 3 pts | Oct 8, 2030 | Mar 31, 2025 |
| S•••••••• P••••• I••• I•• Life sciences | unattributed | 10 | at least $89.3M | 100c | 1 pts | Dec 23, 2032 | Feb 29, 2024 |
| Z•••• C••• M••••••••• B••••• I•• Life sciences | unattributed | 9 | at least $86.4M | 98c | 0 pts | Sep 1, 2029 | Dec 31, 2022 |
| G••••• U• O••• I•• Life sciences | unattributed | 7 | at least $84.1M | 99c | 7 pts | Jul 31, 2030 | Sep 30, 2022 |
| S•••••• L•••• I••••••••• L•• Life sciences | unattributed | 9 | at least $83.7M | 75c | 0 pts | Jul 1, 2031 | Dec 31, 2023 |
| A••••••• I•• Life sciences | unattributed | 4 | at least $80.5M | 101c | 0 pts | Jul 31, 2030 | Dec 31, 2022 |
| I•••••••• C•••••• E••••••• S•• Life sciences | unattributed | 1 | at least $75.5M | 93c | n/a | Sep 1, 2028 | Dec 31, 2021 |
| R••••••••• H•••••••• I•• Life sciences | unattributed | 5 | at least $75.1M | 100c | 0 pts | Mar 1, 2031 | Sep 30, 2022 |
| E•••••• L•• Life sciences | unattributed | 7 | at least $71.3M | 97c | 0 pts | Sep 14, 2030 | Dec 31, 2021 |
| B•••••• C••••••• H••••••••• I••••••••• L•• Life sciences | C••••••••• C•••••• P•••••••• L•• inferred | 5 | at least $70.4M | 100c | 0 pts | Dec 22, 2031 | Dec 31, 2023 |
| D•••• C••• I•••••••• L•• Life sciences | unattributed | 2 | at least $65.2M | 129c | n/a | Oct 4, 2029 | Sep 30, 2024 |
| B••••• H••••• H•••••••• L•• Life sciences | Sponsor not establishedpossible: A•••••••• I••••••••• M••••••••• L•• (a company of this name is on the sponsor's portfolio page) | 6 | at least $64.8M | 100c | 0 pts | May 1, 2028 | Mar 31, 2024 |
| B••• B•••••• P••••••••• I•• Life sciences | unattributed | 4 | at least $61.6M | 100c | 1 pts | Jan 16, 2033 | Dec 31, 2025 |
| I•••••• I•• Life sciences | Sponsor not establishedpossible: E•• C••••••• L•• (Form D signer consensus, grade B) | 4 | at least $61.0M | 94c | 33 pts | Jul 17, 2026 | Dec 31, 2021 |
| S•• E•• C••• H•••••• L•• Life sciences | Sponsor not establishedpossible: M••••••• C•••••• L•• (a company of this name is on the sponsor's portfolio page) | 10 | at least $59.8M | 100c | 1 pts | Oct 5, 2029 | Dec 31, 2022 |
| M•••• P••••••••• I•• Life sciences | Sponsor not establishedpossible: C••••••••• C•••••• P•••••••• L•• (Form D signer consensus, grade B) | 7 | at least $59.5M | 100c | 0 pts | Oct 1, 2031 | Dec 31, 2021 |
| P•• M••••• T•••• L•• Life sciences | unattributed | 5 | at least $58.8M | 99c | 3 pts | Feb 13, 2032 | Mar 31, 2025 |
| E••••• I••••••••• I•• Life sciences | unattributed | 4 | at least $57.6M | 99c | n/a | Aug 31, 2027 | Sep 30, 2021 |
| C••••••• B••••• I•• Life sciences | Sponsor not establishedpossible: C•••• S••••• C•••••• (a company of this name is on the sponsor's portfolio page) | 13 | at least $52.5M | 100c | 0 pts | May 8, 2033 | Dec 31, 2022 |
| A••••••• T••••••••• I•• Life sciences | Sponsor not establishedpossible: L••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 4 | at least $50.4M | 100c | 1 pts | Mar 1, 2031 | Mar 31, 2024 |
| T•••••• B••••• H••••••• L•• Life sciences | unattributed | 9 | at least $49.3M | 86c | 23 pts | May 1, 2028 | Dec 31, 2021 |
| A•••••• B••••••••• I•• Life sciences | unattributed | 3 | at least $48.8M | 105c | 0 pts | Aug 31, 2029 | Dec 31, 2022 |
| S•••• B•••••• I•• Life sciences | Sponsor not establishedpossible: F•••••• S••••• • C•• (a company of this name is on the sponsor's portfolio page) | 7 | at least $47.3M | 83c | 17 pts | Oct 12, 2027 | Dec 31, 2021 |
| C•• H••••••••• P••••••••• I•• Life sciences | M••••• E••••• P•••••••• L•• inferred | 6 | at least $45.7M | 100c | 0 pts | Sep 17, 2031 | Sep 30, 2021 |
| W•••••• T••••••••• I•• Life sciences | unattributed | 11 | at least $45.6M | 100c | 0 pts | Oct 1, 2029 | Dec 31, 2021 |
| G••••• A••••••••• F•••••• L•• Life sciences | unattributed | 2 | at least $43.9M | 101c | n/a | Dec 10, 2032 | Dec 31, 2025 |
| A•• H••••• Life sciences | unattributed | 5 | at least $42.6M | 98c | 2 pts | Aug 1, 2032 | Dec 31, 2024 |
| A••• B••••••••• S•••• F••••• I•• Life sciences | unattributed | 2 | at least $42.6M | 100c | 0 pts | Feb 5, 2031 | Mar 31, 2025 |
Page 1 of 4Next
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.